98%
921
2 minutes
20
Background: Cancer pain is a common symptom among cancer patients, and although opioid drugs are effective, they have side effects and abuse issues. In recent years, mobile apps have gradually been used as digital healthcare for cancer pain management. By visualizing and analyzing the literature on the control of cancer pain through mobile apps, we aim to understand the current research status and hot issues in this field and explore future directions for digital smart healthcare research.
Methods: CiteSpace software was used to visually analyze 252 articles on mobile app-based cancer pain control indexed by the Web of Science core collection database from 1995 to 2024. Microsoft Excel 2021 and GraphPad were used to draw world maps to evaluate the number of national articles and generate trend charts for annual publications.
Results: Visual analysis revealed that the number of publications has been increasing annually. In terms of the number of published articles, the top 3 countries are the United States, China, and Australia. The analysis of highly cited literature indicates that the main apps involved are Pain Buddy, mHealth, The Pain Guard app, The mHealth Pain Squad+, and STAR, which target adults, children, and adolescents. Keywords and citation analysis indicate that quality of life, pain, breast cancer, palliative care, and mobile health may be hotspots and future directions of cancer pain research in mobile apps.
Conclusion: Digital healthcare via mobile apps provides intelligent assistance for treating cancer pain, which is conducive to developing intelligent and painless cancer treatment and management strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12323917 | PMC |
http://dx.doi.org/10.1097/MD.0000000000043603 | DOI Listing |
Am J Clin Hypn
September 2025
Higher Institute of Nursing and Health Technology, Rabat, Morocco.
Gestational trophoblastic tumors (GTTs) encompass a spectrum of neoplastic conditions, including invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. Invasive mole, which frequently develops following a complete hydatidiform mole, represents the most common form. A cancer diagnosis constitutes a profoundly destabilizing experience, often resulting in considerable psychological distress.
View Article and Find Full Text PDFPLoS One
September 2025
Department Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Tattoos and permanent make-up (PMU) gain increasing popularity among the general population. There are indications that pigments or their fragments may translocate within the body, however knowledge about possible systemic adverse effects related to tattoos is very limited. We investigated the prevalence of systemic chronic health effects including cardiovascular diseases, cancer and liver toxicity and their relationship with the presence and characteristics of tattoos and PMU as part of the LIFE-Adult-study, a population-based cohort study.
View Article and Find Full Text PDFMinerva Endocrinol (Torino)
September 2025
Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden -
Adrenal cysts are rare lesions that are increasingly discovered incidentally during radiological examinations conducted without suspicion of adrenal disease. Typically benign, hormonally nonfunctional, and asymptomatic, these lesions may occasionally manifest mass effect symptoms such as pain or abdominal discomfort, particularly in large cysts. Management approaches vary from no follow-up to hormonal investigation, imaging follow-up, or adrenalectomy, especially if the cyst is growing or exhibits an atypical appearance.
View Article and Find Full Text PDFAnn Afr Med
September 2025
Department of Pathology, Dr. Lal Path Labs, New Delhi, India.
Luteinizing hormone-releasing hormone agonists, used in advanced prostate cancer, can cause an initial testosterone surge and may inadequately suppress follicle-stimulating hormone, potentially promoting tumor growth. Injectable gonadotropin-releasing hormone (GnRH) antagonists avoid this surge but have drawbacks like injection-site reactions and monthly dosing. Relugolix, an oral GnRH antagonist, offers rapid testosterone suppression without flare and reduced cardiovascular risks.
View Article and Find Full Text PDFJMIR Serious Games
September 2025
Women's and Newborn Program, Monash Health, 246 Clayton Rd, Melbourne, 3168, Australia, 61 395946666.
Background: Intrauterine devices (IUDs) are safe and effective long-acting reversible contraceptive therapies that are also used as minimally invasive treatment for heavy menstrual bleeding, endometrial hyperplasia, and early-stage endometrial cancer. Despite many advantages, IUDs are underused predominantly due to patient discomfort. Although many techniques have been explored previously in the literature, there is currently little consensus on effective analgesic strategies.
View Article and Find Full Text PDF